Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of Fibromuscular Dysplasia (FMD) center around the understanding and management of this rare vascular disorder characterized by abnormal cell growth in arterial walls. The market is influenced by factors such as diagnosis challenges, treatment modalities, research endeavors, and the impact of FMD on patients' lives.
Market begin with the segmentation of food and mouth disease into market sections which being the recognition that food and mouth disease is a hard disease to diagnose. The disease is commonly overlooked or not diagnosed at all as a result of signs and symptoms being very diverse and similar to other health conditions. Massive campaigns to make people, on the other hand, both health workers and the general public, conscious of earlier detection and diagnosis are very much likely to be a significant element that can bring about this advancement.
Knowledge ofthe amenity, gets the foundation of market dynamics. Although it is a relatively rare condition which only affects certain people, it’s impact on them can in no way be underestimated, giving rise to such health issues as narrowing of arteries, aneurysms, and damage to vital organs. Identifying the contribution empowers healthcare strategies and resource needs for an effective treatment! One factor that substantially contributes to the burden of chronic diseases is their global prevalence.
The market conditions for FMD are all dependent on the number of treatment options which are available. These vary from blood pressure management using medications, endovascular procedures, or in extreme cases, surgical solutions may be employed. The efficiency of this therapy takes the position that the risk and benefits of this therapy largely influence clinical practices.
On going research in addition to market dynamics, aid immensely through identification of disease dynamics and therapeutic target exploration. Through clinical trials, and through collaborative work of researchers, the knowledge about the condition is being sharpened, while the treatments are updated bringing about better results.
Patient advocacy organizations are very important in market dynamic because they inform the public, help patients and exacteuie research funding. These clusters, which are policy formulators as well as implementing agents, contribute to research initiatives and patient-centric care, which are critical in mitigation of such diseases as Familial Mediterranean Fever in affected persons.
Market dynamics extend globally, but regional variations in healthcare infrastructure, access to specialized care, and cultural factors play a role. Understanding these trends and considerations is essential for pharmaceutical companies, healthcare providers, and policymakers to tailor strategies that address the unique challenges faced by individuals with FMD in different regions.
The regulatory environment contributes to market dynamics. Approval processes for new therapies, reimbursement policies, and regulatory compliance impact the accessibility of treatment options. Market strategies need to align with regional regulations to ensure the successful introduction and adoption of FMD treatments.
Fibromuscular Dysplasia Market Highlights:
Fibromuscular Dysplasia Market Scenario:
Fibromuscular dysplasia (FMD) is a disease that causes abnormal cell development in the artery wall, which results in narrowing, i.e., stenosis, and enlargement, i.e., aneurysm of the medium-sized arteries in the body.
According to a study published in the Insights into Imaging in 2015, it is found that the prevalence of fibromuscular dysplasia is estimated to be 4%-6% in the renal arteries and 0.3%-3 % in the cervico-encephalic arteries. Fibromuscular dysplasia is most frequently revealed in the kidneys of young patients associated with resistant hypertension secondary to fibrodysplastic renal artery stenosis. It is also reported that fibromuscular dysplasia is found in around 1% of the hypertensive patients, and is the second leading cause of renovascular hypertension after atherosclerotic disease.
Notably, rising prevalence of fibromuscular dysplasia and increasing R&D expenditure are the key factors driving the fibromuscular dysplasia market. In the year 2016, the R&D expenditure in the pharmaceutical Industry was USD 43,047.9 million, suggested by European Federation of Pharmaceutical Industries and Association.
Various other factors such as increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the fibromuscular dysplasia market. According to the Eurostat data, it is observed that among the European Union Member States, the highest value of healthcare expenditure was recorded in Germany, i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion, in 2014.
Despite these driving factors, there are some challenges with fibromuscular dysplasia market. Side-effects of treatment, expiration of patented drugs, the presence of misbranded drugs, and poor healthcare system in low and middle-income countries may hamper the growth of the market to a great extent over the review period 2017-2023.
It is estimated that the fibromuscular dysplasia market is expected to grow at a CAGR of 7.5% during the forecast period of 2017-2023.
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Medical Device Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Segmentation
The fibromuscular dysplasia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the fibromuscular dysplasia market is classified as multifocal fibromuscular dysplasia, and focal fibromuscular dysplasia.
On the basis of the diagnosis, the fibromuscular dysplasia market is classified as physical examination, blood test, catheter-based angiography, doppler ultrasound, computerized tomography (CT) angiogram, magnetic resonance imaging (MRI), and others
On the basis of the treatment, the fibromuscular dysplasia market is classified as surgery, medication, and others. The surgery segment is further sub-segmented into percutaneous transluminal angioplasty (PTA), and surgical revascularization. The medication segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, calcium channel blockers, and beta blockers.
On the basis of the end-user, the fibromuscular dysplasia market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the fibromuscular dysplasia market owing to the rising prevalence of fibromuscular dysplasia and high healthcare expenditure. In 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion, and hospital care accounted for a share of 32.3%, suggested by Centers for Disease Control and Prevention.
Europe holds the second position in the fibromuscular dysplasia market. It is found that the rising research & development expenditure, and amendments in the reimbursement policies in the healthcare are likely to drive the European market.
The Asia Pacific region is the fastest growing fibromuscular dysplasia market owing to the developing healthcare technology, and huge patient pool. Healthcare expenditure of various Asia Pacific countries is also growing steadily. As per the Australian Institute of Health and Welfare in the years 2015-2016, the total healthcare expenditure in Australia was recorded to be USD 170.4 billion, which was around 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.
Key Players
Some of the key players in the fibromuscular dysplasia market are Alkermes Pharma Ireland Limited, ALVOGEN, Aspen Surgical Products, Inc., AstraZeneca, B. Braun Melsungen AG, Bayer Healthcare Pharmaceuticals Inc., Becton, Dickinson and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd, Ethicon, Inc., Merck, Novartis, Pfizer, Sanofi-Aventis, Smith & Nephew plc; Medtronic, Stryker Corporation, and Watson Pharma Private Limited.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
